Literature DB >> 32483728

Advances in the Functional Assessment of Patients with Sarcoma.

Duncan C Ramsey1, Kenneth R Gundle2,3.   

Abstract

Functional assessment of patients with osteosarcoma may yield unique insights into the guide and advance treatment. A range of patient-reported outcomes has been validated, including general health and condition-specific measures as well as computer adaptive testing. Health state utility measures, which facilitate comparative-effectiveness research, are also available. Beyond these surveys, and laboratory-dependent gait analyses, is the potential for real-world evaluation through research-oriented and consumer-oriented accelerometers. Initial studies have shown promising validity of these activity trackers and may also have implications for traditional oncologic outcomes.

Entities:  

Keywords:  Accelerometers; Activity monitoring; Computer adaptive testing; Gait analysis; Health state utilities; Health-related quality of life; Osteosarcoma; Patient-reported outcomes; Sarcoma

Mesh:

Year:  2020        PMID: 32483728     DOI: 10.1007/978-3-030-43032-0_3

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  41 in total

1.  The impact of misclassification due to survey response fatigue on estimation and identifiability of treatment effects.

Authors:  Brian L Egleston; Suzanne M Miller; Neal J Meropol
Journal:  Stat Med       Date:  2011-09-23       Impact factor: 2.373

2.  Patient-Reported Functional and Quality of Life Outcomes in a Large Cohort of Long-Term Survivors of Ewing Sarcoma.

Authors:  Bradley J Stish; Safia K Ahmed; Peter S Rose; Carola A Arndt; Nadia N Laack
Journal:  Pediatr Blood Cancer       Date:  2015-08-14       Impact factor: 3.167

Review 3.  Limb salvage and amputation in survivors of pediatric lower-extremity bone tumors: what are the long-term implications?

Authors:  Rajaram Nagarajan; Joseph P Neglia; Denis R Clohisy; Leslie L Robison
Journal:  J Clin Oncol       Date:  2002-11-15       Impact factor: 44.544

Review 4.  Quality of life measures in soft tissue sarcoma.

Authors:  Kenneth R Gundle; Amy M Cizik; Robin L Jones; Darin J Davidson
Journal:  Expert Rev Anticancer Ther       Date:  2014-11-07       Impact factor: 4.512

5.  Development of a measure of physical function for patients with bone and soft tissue sarcoma.

Authors:  A M Davis; J G Wright; J I Williams; C Bombardier; A Griffin; R S Bell
Journal:  Qual Life Res       Date:  1996-10       Impact factor: 4.147

Review 6.  Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology.

Authors:  Ethan Basch; Amy P Abernethy; C Daniel Mullins; Bryce B Reeve; Mary Lou Smith; Stephen Joel Coons; Jeff Sloan; Keith Wenzel; Cynthia Chauhan; Wayland Eppard; Elizabeth S Frank; Joseph Lipscomb; Stephen A Raymond; Merianne Spencer; Sean Tunis
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

7.  Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials.

Authors:  Chantal Quinten; Corneel Coens; Murielle Mauer; Sylvie Comte; Mirjam A G Sprangers; Charles Cleeland; David Osoba; Kristin Bjordal; Andrew Bottomley
Journal:  Lancet Oncol       Date:  2009-08-18       Impact factor: 41.316

8.  Trends in childhood cancer incidence in the U.S. (1992-2004).

Authors:  Amy M Linabery; Julie A Ross
Journal:  Cancer       Date:  2008-01-15       Impact factor: 6.860

9.  Functional outcome after endoprosthetic limb-salvage therapy of primary bone tumours--a comparative analysis using the MSTS score, the TESS and the RNL index.

Authors:  P U Tunn; D Pomraenke; U Goerling; P Hohenberger
Journal:  Int Orthop       Date:  2007-08-15       Impact factor: 3.075

10.  Cultural adaptation, translation and validation of a functional outcome questionnaire (TESS) to Portuguese with application to patients with lower extremity osteosarcoma.

Authors:  Daniela Saraiva; Beatriz de Camargo; Aileen M Davis
Journal:  Pediatr Blood Cancer       Date:  2008-05       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.